Splenda® improves tolerance of oral potassium citrate supplementation for prevention of stone formation: Results of a randomized double-blind trial

Journal of Endourology

Volumn 25, Issue 9, 2011, Pages 1541-1545

  Mechlin, Clay ^a   Kalorin, Carmin ^a   Asplin, John ^b   White, Mark ^a,c  

^a ALBANY MEDICAL COLLEGE   (United States)

^b LithoLink Corporation   (United States)

^c Urological Institute of Northeastern New York   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITRATE POTASSIUM; CITRIC ACID; CYTRA K; SPLENDA; SUCRALOSE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MALE; PALATABILITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; STONE FORMATION; SUPPLEMENTATION; TASTE ACUITY; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DEMOGRAPHY; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; HUMANS; KIDNEY CALCULI; MALE; POTASSIUM CITRATE; SUCROSE; SWEETENING AGENTS; TASTE; URINALYSIS; YOUNG ADULT;

EID: 80052619441     PISSN: 08927790     EISSN: 1557900X     Source Type: Journal    
DOI: 10.1089/end.2010.0663     Document Type: Article

References (26)

1. Lotan Y, Pearle M. Economics of stone management. Urol Clin North Am 2007;34:443-453. (Pubitemid 47176121)
2. Stamatelou K, Francis M, Jones C, et al. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003;63:1817-1823. (Pubitemid 36513328)
3. Sutherland JW, Parks JH, Coe FL. Recurrence after a single renal stone in a community practice. Miner Electrolyte Metab 1985;11:267-269. (Pubitemid 15001516)
4. Williams RE. Long-term survey of 538 patients with upper urinary tract stone. Br J Urol 1963;35:416-437.
5. Ljunghall S, Danielson BG. A prospective study of renal stone recurrences. Br J Urol 1984;56:122-124. (Pubitemid 14128928)
6. Pearle M, Roehrborn C, Pak C. Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 1999;13:679-685.
7. Chandhoke P. When is medical prophylaxis cost-effective for recurrent calcium stones? J Urol 2002;168:937-940.
8. Pak C, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 1986;30:422-428. (Pubitemid 16029514)
9. Goldberg H, Grass L, Vogl R, et al. Urine citrate and renal stone disease. CMAJ 1989;141:217-221. (Pubitemid 19195785)
10. Pearle MS, Lotan Y. Urinary lithiasis: Etiology, epidemiology, and pathogenisis. In: Kavoussi LR, Novick AC, Partin AW, Peters CA, eds. Campbell-Walsh Urology. 9th ed. Philadelphia: Saunders, 2007.
11. Barcelo P, Wuhl O, Servitge E, et al. Randomized doubleblind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 1993;150:1761-1764. (Pubitemid 24350792)
12. Lee Y, Huang W, Tsai J, Huang JK. The efficacy of potassium citrate based medical prophylaxis for preventing upper urinary tract calculi: A midterm followup study. J Urol 1999;161:1453-1457. (Pubitemid 29420794)
13. Soygür T, Akbay A, Küpeli S. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: A randomized controlled trial. J Endourol 2002;16:149-152. (Pubitemid 34438765)
14. Sarica K, Erturhan S, Yurtseven C, et al. Effect of potassium citrate therapy on stone recurrence and regrowth after extracorporeal shockwave lithotripsy in children. J Endourol 2006;20:875-879. (Pubitemid 44907015)
15. Ettinger B, Pak C, Citron J, et al. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 1997;158:2069-2073. (Pubitemid 27481329)
16. Jendle-Bengten C, Tiselius H. Long-term follow-up of stone formers treated with a low dose of sodium potassium citrate. Scand J Urol Nephrol 2000;34:36-41. (Pubitemid 30396717)
17. Tracy C, Pearle M. Update on the medical management of stone disease. Curr Opin Urol 2009;19:200-2004.
18. Schwille P, Herrmann U, Wolf C, et al. Citrate and recurrent idiopathic calcium urolithiasis. A longitudinal pilot study on the metabolic effects of oral potassium citrate administered over the short-, medium- and long-term medication of male stone patients. Urol Res 1992;20:145-155.
19. Koff SG, Paquette EL, Cullen J, et al. Comparison between lemonade and potassium citrate and impact on urine pH and 24-hour urine parameters in patients with kidney stone formation. Urology 2007;69:1013-1016. (Pubitemid 46891572)
20. Kang DE, Sur RL, Haleblian GE, et al. Long-term lemonade based dietary manipulation in patients with hypocitraturic nephrolithiasis. J Urol 2007;177:1358-1362. (Pubitemid 46436008)
21. Passman CM, Holmes RP, Knight J, et al. Effect of soda consumption on urinary stone risk parameters. J Endourol 2009;23:347-350.
22. Grice H, Goldsmith L. Sucralose-an overview of the toxicity data. Food Chem Toxicol 2000;38(suppl 2):S1-S6.
23. Weihrauch M, Diehl V. Artificial sweeteners-do they bear a carcinogenic risk? Ann Oncol 3004;15:1460-1465.
24. Roberts A, Renwick A, Sims J, et al. Sucralose metabolism and pharmacokinetics in man. Food Chem Toxicol 2000;38(suppl 2):S31-S41.
25. Drustore.com, 2010.
26. Potassium citrate: Official FDA information, side effects and uses. Drugs.com. http://www.drugs.com. Accessed April 15, 2011.